Top

Published in:

01-05-2011 | Original Research

Role of Parathyroid Hormone in Bone Fragility of Postmenopausal Women with Vitamin D Insufficiency

Authors: Mika Yamauchi, Hiroshi Kaji, Kiyoko Nawata, Shin Takaoka, Toru Yamaguchi, Toshitsugu Sugimoto

Published in: Calcified Tissue International | Issue 5/2011

Abstract

Vitamin D insufficiency is related to an increase in PTH, which might be critical for an increase in bone fragility. However, the role of endogenous PTH in vitamin D insufficiency-induced fracture risk remains unclear. The present study was performed to examine the relationships among vitamin D insufficiency, bone fragility, and PTH in 202 Japanese postmenopausal women. Serum 25-hydroxyvitamin D (25[OH]D) levels were measured. The percentages of subjects with 25(OH)D levels below 10, 15, and 20 ng/ml were 5.0, 41.0, and 80.7%, respectively. Serum 25(OH)D levels were negatively related to age and serum levels of Cr and PTH; they were positively related to bone mineral density (BMD). In multiple regression analysis, BMD was significantly related to 25(OH)D levels when adjusted for age, body mass index (BMI), and serum levels of Cr and PTH. Multiple logistic regression analysis showed that lower 25(OH)D levels were significantly related to prevalent fracture risk when adjusted for age, BMI, serum levels of Cr and PTH, as well as femoral neck BMD. The proportion of subjects with prevalent fractures was significantly higher in the group with lower PTH and lower 25(OH)D than in the group with lower PTH and higher 25(OH)D or higher PTH and higher 25(OH)D. In conclusion, vitamin D insufficiency was found to be related to prevalent fracture risk independently of PTH. Functional hypoparathyroidism, rather than functional hyperparathyroidism, might be a risk factor for bone fragility in vitamin D insufficiency.

Mithal A, Wahl DA, Bonjour JP et al (2009) Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 20:1807–1820PubMedCrossRef

Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501PubMedCrossRef

Priemel M, von Domarus C, Klatte TO et al (2010) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 25:305–312PubMedCrossRef

Abrams SA, Griffin IJ, Hawthorne KM, Gunn SK, Gundberg CM, Carpenter TO (2005) Relationships among vitamin D levels, parathyroid hormone, and calcium absorption in young adolescents. J Clin Endocrinol Metab 90:5576–5581PubMedCrossRef

Harkness L, Cromer B (2005) Low levels of 25-hydroxyvitamn D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos Int 16:109–113PubMedCrossRef

Snijder MB, van Dam RM, Visser M et al (2005) Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 90:4119–4123PubMedCrossRef

Pepe J, Romahnoli E, Nofroni I et al (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 16:805–812PubMedCrossRef

Okazaki R, Sugimoto T, Kaji H et al (2010) Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D₃ load in Japanese subjects. J Bone Miner Metab 29:103–110PubMedCrossRef

Hannan MT, Litman HJ, Araujo AB et al (2008) Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J Clin Endocrinol Metab 93:40–46PubMedCrossRef

10.

Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B et al (2009) Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 24:935–942PubMedCrossRef

11.

Kuchuk NO, Pluijm SM, van Schoor NM, Looman CW, Smit JH, Lips P (2009) Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab 94:1244–1250PubMedCrossRef

12.

Kuchuk NO, van Schoor NM, Pluijm SM, Chines A, Lips P (2009) Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective. J Bone Miner Res 24:693–701PubMedCrossRef

13.

Ensrud KE, Taylor BC, Paudel ML et al (2009) Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab 94:2773–2780PubMedCrossRef

14.

Visser M, Deeg DJ, Lips P (2003) Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab 88:5766–5772PubMedCrossRef

15.

Suzuki T, Kwon J, Kim H et al (2008) Low serum 25-hydroxyvitamin D levels associated with falls among Japanese community-dwelling elderly. J Bone Miner Res 23:1309–1317PubMedCrossRef

16.

Snijder MB, van Schoor NM, Pluijm SM, van Dam RM, Visser M, Lips P (2006) Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J Clin Endocrinol Metab 91:2980–2985PubMedCrossRef

17.

Cauley JA, Parimi N, Ensrud KE et al (2010) Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res 25:545–553PubMedCrossRef

18.

Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res 23:143–150PubMedCrossRef

19.

Ruohola JP, Laaksi I, Ylikomi T et al (2006) Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men. J Bone Miner Res 21:1483–1488PubMedCrossRef

20.

Cauley JA, Lacroix AZ, Wu L et al (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149:242–250PubMed

21.

Garnero P, Munoz F, Sornay-Rendu E, Delmas PD (2007) Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 40:716–722PubMedCrossRef

22.

Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716PubMedCrossRef

23.

Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B (1999) Primary hyperparathyroidism and a risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707PubMedCrossRef

24.

Kaji H, Yamauchi M, Chihara K, Sugimoto T (2008) Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients with glucocorticoid. Horm Metab Res 40:60–65PubMedCrossRef

25.

Kaji H, Kuroki Y, Murakawa Y et al (2010) Effect of alendronate on bone metabolic indices and bone mineral density in patients with high-dose glucocorticoid: a prospective study. Osteoporos Int 21:1565–1571PubMedCrossRef

26.

Papadimitropoulos E, Wells G, Shea B, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569

27.

Schmidt-Gayk H, Spanuth E, Kotting J et al (2004) Performance evaluation of automated assays for β-CrossLaps, N-MID-osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 42:90–95PubMedCrossRef

28.

Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188–196PubMedCrossRef

29.

Leino A, Turpeinen U, Koskinen P (2008) Automated measurement of 25-OH vitamin D₃ on the Roche modular E170 analyzer. Clin Chem 54:2059–2062PubMedCrossRef

30.

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a SQ technique. J Bone Miner Res 8:1137–1148PubMedCrossRef

31.

Lewiecki EM, Laster AJ (2006) Clinical review: clinical applications of vertebral fracture assessment by dual-energy X-ray absorptioometry. J Clin Endocrinol Metab 91:4215–4222PubMedCrossRef

32.

Vignali E, Viccica G, Diacinti D et al (2009) Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 94:2306–2312PubMedCrossRef

33.

Fuerst T, Wu C, Genant HK et al (2009) Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting. Osteoporos Int 20:1199–1205PubMedCrossRef

34.

Nakamura K, Tsugawa N, Saito T et al (2008) Vitamin D status, bone mass, and bone metabolism in 600 home-dwelling postmenopausal Japanese women: Yokogoshi study. Bone 42:271–277PubMedCrossRef

35.

Holick MF, Siris ES, Binkley N et al (2005) Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215–3224PubMedCrossRef

36.

Levis S, Gomez A, Jimenez C et al (2005) Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab 90:1557–1562PubMedCrossRef

37.

Thomas MK, Lloyd-Jones DM, Thadhani RI et al (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783PubMedCrossRef

38.

Ooms ME, Lips P, Roos JC et al (1995) Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res 10:1177–1184PubMedCrossRef

39.

Inoue Y, Kaji H, Hisa I et al (2008) Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr J 55:57–65PubMedCrossRef

40.

Cummings SR, Browner WS, Bauer D et al (1998) Endogenous hormone and the risk of hip and vertebral fractures among older women. N Engl J Med 339:733–738PubMedCrossRef

41.

Roddam AW, Neale R, Appleby P, Allen NE, Tipper S, Key TJ (2007) Association between plasma 25-hydroxyvitamin D levels and fracture risk: the EPIC-Oxford study. Am J Epidemiol 166:1327–1336PubMedCrossRef

42.

Melhus H, Snellman G, Gedeborg R et al (2010) Plasma 25-hydroxyvitamn D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab 95:2637–2645PubMedCrossRef

43.

Wicherts IS, van Schoor NM, Boeke AJP et al (2007) Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 92:2058–2065PubMedCrossRef

44.

Sahota O, Mundey MK, San P, Godber IM, Lawson N, Hosking DJ (2004) The relationship between vitamin D and parathyroid hormone, calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319PubMedCrossRef

45.

Sahota O, Gaynor K, Harwood RH, Hosking DJ (2001) Hypovitaminosis D and “functional hypoparathyroidism”—the NoNoF (Nottingham Neck of Femur) study. Age Ageing 30:467–472PubMedCrossRef

46.

Rejnmark L, Vestergaard P, Brot C, Mosekilde L (2008) Parathyroid response to vitamin D insufficiency: relations to bone density, body composition, and to life style characteristics. Clin Endocrinol 69:29–35CrossRef

47.

Stein MS, Wark JD, Scherer SC et al (1999) Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. J Am Geriatr Soc 47:1195–1201PubMed

48.

Rubin MR, Dempster DW, Zhou H et al (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23:2018–2024PubMedCrossRef

Title: Role of Parathyroid Hormone in Bone Fragility of Postmenopausal Women with Vitamin D Insufficiency
Authors: Mika Yamauchi
Hiroshi Kaji
Kiyoko Nawata
Shin Takaoka
Toru Yamaguchi
Toshitsugu Sugimoto
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Calcified Tissue International / Issue 5/2011
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-011-9464-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Role of Parathyroid Hormone in Bone Fragility of Postmenopausal Women with Vitamin D Insufficiency

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Microdamage Accumulation Changes According to Animal Mass: An Intraspecies Investigation

The Three-Dimensional Morphometry and Cell–Cell Communication of the Osteocyte Network in Chick and Mouse Embryonic Calvaria

Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study

Three Novel Mutations in the PHEX Gene in Chinese Subjects with Hypophosphatemic Rickets Extends Genotypic Variability

Minerals Form a Continuum Phase in Mature Cancellous Bone

No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page